VIMTA LABS Latest Share Price (VIMTALABS)
TODAY IN ONE LINE
VIMTALABS slipped 1.0% on light volume, in line with Nifty's -0.4% move.
With a market cap of ₹2,736.89 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
VIMTA LABS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 14.3% YoY
- ●High Capital EfficiencyROCE of 17.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 17.0%
- ●Healthy Operating MarginsOPM is structurally strong at 25.8%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 73.2% YoY
- ●Rising Receivables vs SalesReceivables grew 20.1% outpacing sales growth of 19.3%
Latest VIMTA LABS News
What changed recently?
Recent events, corporate actions, and announcements.
VIMTA LABS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VIMTA LABS, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
VIMTA LABS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for VIMTA LABS — derived from the latest tape, not yesterday's close.
VIMTA LABS last traded at ₹610.15 with an intraday range of ₹607.1–₹626.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹610.15| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 660.87 | +50.72 | +8.31% |
| R3 | 641.47 | +31.32 | +5.13% |
| R2 | 633.98 | +23.83 | +3.91% |
| R1 | 622.07 | +11.92 | +1.95% |
| PIVOT | 614.58 | 4.43 | 0.73% |
| CURRENT | 610.15 | — | — |
| S1 | 602.67 | -7.48 | -1.23% |
| S2 | 595.18 | -14.97 | -2.45% |
| S3 | 583.27 | -26.88 | -4.41% |
| S4 | 563.87 | -46.28 | -7.59% |
VIMTALABS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹617.65–₹625
Trading Inside opening range
VIMTA LABS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for VIMTA LABS — consolidated or standalone — with margins, YoY growth and key ratios inline.
VIMTA LABS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,736.89 Cr. and reported EPS of ₹4.71.
| Metric | Mar 2023 | Mar 2024 |
|---|---|---|
| Revenue from Operations | 318 | 318 ▲ 0.0% |
| Sales Growth YoY %Derived | 14.34% | 0.02% |
| Other Income | 3 | 4 ▲ 16.3% |
| Total Income | 322 | 322 ▲ 0.2% |
| 74 | 76 ▲ 3.3% | |
| Gross ProfitDerived | 244 | 242 ▼ 1.0% |
| Gross Margin %Derived | 76.79% | 76.03% |
| 149 | 155 ▲ 3.9% | |
| EBITDA (Operating Profit)Derived | 95 | 87 ▼ 8.6% |
| OPM %Derived | 29.83% | 27.27% |
| 33 | 36 ▲ 8.9% | |
| Profit Before Tax (PBT) | 65 | 54 ▼ 16.2% |
| 17 | 13 ▼ 19.9% | |
| Effective Tax %Derived | 25.89% | 24.73% |
| Total Profit for Period | 48 | 41 ▼ 14.9% |
| Net Profit (Owner's PAT)Derived | 48 | 41 ▼ 14.9% |
| Net Profit Margin %Derived | 15.14% | 12.89% |
| PAT Growth YoY %Derived | 16.55% | -14.87% |
| Earnings Per Share (EPS ₹) | 10.88 | 9.25 ▼ 15.0% |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.2% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 796.2% |
| Total Expenses (incl. D&A & Interest) | 257 | 268 ▲ 4.3% |
| Material Cost % of RevenueDerived | 23.18% | 23.94% |
| Employee Cost % of RevenueDerived | 28.62% | 31.20% |
| Other Cost % of RevenueDerived | 18.34% | 17.56% |
| Interest Coverage (x)Derived | 24.27x | 24.79x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 213 | 213 ▲ 0.0% | 181 ▼ 15.0% | 211 ▲ 16.6% | 278 ▲ 32.1% | 318 ▲ 14.3% | 318 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | -15.02% | 16.58% | 32.09% | 14.34% | 0.02% | |
| Other Income | 2 | 2 ▲ 0.0% | 3 ▲ 56.6% | 1 ▼ 72.5% | 1 ▲ 74.8% | 3 ▲ 137.7% | 4 ▲ 16.3% | |
| Total Income | 215 | 215 ▲ 0.0% | 184 ▼ 14.4% | 212 ▲ 15.1% | 280 ▲ 32.3% | 322 ▲ 15.0% | 322 ▲ 0.2% | |
58 | 58 ▲ 0.0% | 54 ▼ 8.0% | 61 ▲ 13.7% | 79 ▲ 29.6% | 74 ▼ 6.7% | 76 ▲ 3.3% | ||
| Gross ProfitDerived | 154 | 154 ▲ 0.0% | 127 ▼ 17.7% | 150 ▲ 17.8% | 199 ▲ 33.1% | 244 ▲ 22.7% | 242 ▼ 1.0% | |
| Gross Margin %Derived | 72.53% | 72.53% | 70.26% | 70.99% | 71.54% | 76.79% | 76.03% | |
97 | 97 ▲ 0.0% | 97 ▲ 0.4% | 97 ▼ 0.4% | 119 ▲ 23.0% | 149 ▲ 25.8% | 155 ▲ 3.9% | ||
| EBITDA (Operating Profit)Derived | 58 | 58 ▲ 0.0% | 30 ▼ 48.0% | 53 ▲ 76.8% | 80 ▲ 51.6% | 95 ▲ 18.2% | 87 ▼ 8.6% | |
| OPM %Derived | 27.06% | 27.06% | 16.57% | 25.14% | 28.85% | 29.83% | 27.27% | |
24 | 24 ▲ 0.0% | 25 ▲ 1.5% | 25 ▲ 2.2% | 24 ▼ 6.5% | 33 ▲ 41.3% | 36 ▲ 8.9% | ||
| Profit Before Tax (PBT) | 35 | 35 ▲ 0.0% | 8 ▼ 76.5% | 29 ▲ 245.1% | 56 ▲ 95.1% | 65 ▲ 16.7% | 54 ▼ 16.2% | |
10 | 10 ▲ 0.0% | 1 ▼ 85.5% | 7 ▲ 400.7% | 14 ▲ 101.2% | 17 ▲ 17.2% | 13 ▼ 19.9% | ||
| Effective Tax %Derived | 27.97% | 27.97% | 17.23% | 25.00% | 25.78% | 25.89% | 24.73% | |
| Total Profit for Period | 25 | 25 ▲ 0.0% | 7 ▼ 73.0% | 21 ▲ 212.7% | 41 ▲ 93.1% | 48 ▲ 16.6% | 41 ▼ 14.9% | |
| Net Profit (Owner's PAT)Derived | 25 | 25 ▲ 0.0% | 7 ▼ 73.0% | 21 ▲ 212.7% | 41 ▲ 93.1% | 48 ▲ 16.6% | 41 ▼ 14.9% | |
| Net Profit Margin %Derived | 11.90% | 11.90% | 3.79% | 10.16% | 14.85% | 15.14% | 12.89% | |
| PAT Growth YoY %Derived | — | — | -72.96% | 212.71% | 93.09% | 16.55% | -14.87% | |
| Earnings Per Share (EPS ₹) | 5.72 | 5.72 ▲ 0.0% | 1.55 ▼ 72.9% | 4.84 ▲ 212.3% | 9.35 ▲ 93.2% | 10.88 ▲ 16.4% | 9.25 ▼ 15.0% | |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.1% | 4 ▲ 0.2% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | -0 ▲ 60.7% | 0 ▲ 152.9% | -0 ▼ 303.0% | -0 ▲ 87.2% | -0 ▼ 796.2% | |
| Total Expenses (incl. D&A & Interest) | 179 | 179 ▲ 0.0% | 175 ▼ 2.2% | 183 ▲ 4.3% | 224 ▲ 22.4% | 257 ▲ 14.5% | 268 ▲ 4.3% | |
| Material Cost % of RevenueDerived | 27.84% | 27.84% | 29.54% | 27.59% | 28.36% | 23.18% | 23.94% | |
| Employee Cost % of RevenueDerived | 27.87% | 27.87% | 34.02% | 28.85% | 27.30% | 28.62% | 31.20% | |
| Other Cost % of RevenueDerived | 17.60% | 17.60% | 19.67% | 17.01% | 15.39% | 18.34% | 17.56% | |
| Interest Coverage (x)Derived | 8.21x | 8.21x | 2.39x | 13.78x | 38.02x | 24.27x | 24.79x |
VIMTA LABS segment analysis : revenue and profit mix.
Disclosed business segments at VIMTA LABS with their share of revenue and profit, switchable between consolidated and standalone reporting.
VIMTA LABS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for VIMTA LABS.
Our AI distills the core fundamental drivers supporting VIMTA LABS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
VIMTA LABS's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
VIMTA LABS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VIMTA LABS is highlighted for quick read-across.
Quick Compare
VIMTA LABS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for VIMTA LABS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
VIMTA LABS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VIMTA LABS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VIMTA LABS stood at 42.6% of traded volume, against a 20-day average of 38.6%.
VIMTA LABS announcements: results, concalls, ratings, M&A.
Filings VIMTA LABS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VIMTA LABS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 136 documents below.
Allotment of Securities
Vimta Labs Limited has informed the Exchange regarding allotment of 12955 securities pursuant to ESOP/ESPS at its meeting held on September 16, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Vimta Labs Limited has informed the Exchange about Schedule of meet
Credit Rating
Vimta Labs Limited has informed the Exchange about Credit Rating
Spurt in Volume
Significant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant…
Spurt in Volume
Significant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant…
Investor decks & rating reports.
VIMTA LABS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VIMTA LABS has declared, sequenced by announce and record date.
VIMTA LABS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
VIMTA LABS insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in VIMTA LABS as reported to SEBI — buying and selling signals from the people who know the business best.
VIMTA LABS insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jagadeesh Kodali | Insider | 25 Feb 2026 | buy | +5.0 K | ₹23.2 L | ₹464.00 |
| Jagadeesh Kodali | Insider | 25 Feb 2026 | buy | +5.0 K | ₹23.2 L | ₹464.00 |
| Jagadeesh Kodali | Insider | 25 Feb 2026 | buy | +5.0 K | ₹23.2 L | ₹464.00 |
| VASIREDDI VEERABHADRA PRASAD | Insider | 28 May 2025 | sell | −9.50 L | ₹92.76 Cr. | ₹976.40 |
| SUJANI VASIREDDI | Insider | 28 May 2025 | buy | +3.50 L | ₹34.17 Cr. | ₹976.40 |
| RAJYA LAKSHMI VASIREDDI | Insider | 28 May 2025 | buy | +6.00 L | ₹58.58 Cr. | ₹976.40 |
| Harriman Vungal | Insider | 12 Feb 2025 | sell | −2.9 K | ₹31.43 L | ₹1,083.66 |
| Harriman Vungal | Insider | 06 Feb 2025 | sell | −1.2 K | — | — |
| Harriman Vungal | Insider | 06 Feb 2025 | sell | −975 | ₹10.12 L | ₹1,038.00 |
About VIMTA LABS: business, sector, key facts.
What VIMTA LABS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VIMTA LABS operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: VIMTALABS, BSE: 524394.
Vimta Labs Limited is a prominent contract research and testing services provider operating both domestically in India and internationally. Their core business revolves around offering comprehensive support to a diverse range of industries, enabling them to streamline their research, development, and quality control processes.
A significant portion of Vimta Labs' services centers on the biopharmaceutical sector. They provide crucial support throughout the drug lifecycle, encompassing preclinical and clinical research phases, as well as analytical services. This allows biopharmaceutical companies to outsource complex research tasks, benefiting from Vimta's expertise and infrastructure.
Beyond pharmaceuticals, Vimta Labs caters to the needs of medical device companies by offering preclinical research and testing services. This ensures the safety and efficacy of medical devices before they reach the market. Their services extend to agrochemical and specialty chemical companies, assisting with contract research and testing critical for product development and regulatory compliance.
Food safety and quality assurance forms another important pillar of Vimta Labs' business. They provide comprehensive testing and analytical development services to a broad spectrum of stakeholders in the food industry, including manufacturers, processors, and regulatory bodies. This includes testing for various food products and materials.
Furthermore, Vimta Labs offers environmental regulatory services, crucial for industries facing environmental impact assessments and post-project monitoring requirements. This support extends to a wide range of sectors such as power, infrastructure, cement, oil and gas, and mining. They also provide EMI/EMC testing for electronic and electrical products and components.
In summary, Vimta Labs provides a broad portfolio of testing and research services across numerous sectors. Their diverse clientele includes those in agriculture, biologics, personal care, medical devices, specialty chemicals, food, electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, and environmental sectors. This wide-ranging expertise and established presence make Vimta Labs a significant player in the contract research and testing landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- INDEGENE (INDGN) Share PricePeer
- SUVEN LIFE SCIENCES (SUVEN) Share PricePeer
- SYNGENE INTERNATIONAL (SYNGENE) Share PricePeer
- TAKE (TAKE) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about VIMTA LABS (VIMTALABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of VIMTA LABS (VIMTALABS)?
The current share price of VIMTA LABS (VIMTALABS) is ₹610.15. Today, the stock has declined by ₹5.90 (0.96%), trading in a range of ₹607.10 to ₹626.50. The stock opened at ₹622.60 with a trading volume of 1,54,392 shares.
02Is VIMTA LABS stock a good investment for long-term?
VIMTA LABS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,736.89 Cr., P/E ratio of 0, ROE of 16.97%, and ROCE of 17.48%. The dividend yield stands at 0.33%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of VIMTA LABS stock?
The 52-week high price of VIMTA LABS (VIMTALABS) is ₹828.35, while the 52-week low is ₹376.05. Currently trading at ₹610.15, the stock is 62.25% above its 52-week low and 26.34% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy VIMTA LABS stock at the current price?
Whether to buy VIMTA LABS stock at ₹610.15 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a loss of 0.96%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of VIMTA LABS and when is the next dividend?
VIMTA LABS offers a dividend yield of 0.33%, which means for every ₹100 invested at the current price of ₹610.15, you can expect to receive approximately ₹0.33 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of VIMTA LABS?
VIMTA LABS's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0, ROE: 16.97%, ROCE: 17.48%, Dividend Yield: 0.33%, EPS: ₹4.71, Book Value: ₹102.28, and Debt-to-Equity: 0.01. The company's market cap stands at ₹2,736.89 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is VIMTA LABS stock performing today in the market?
VIMTA LABS stock opened at ₹622.60 and is currently trading at ₹610.15, showing a decline of ₹5.90 (0.96%). The intraday high is ₹626.50 and low is ₹607.10. The trading volume stands at 1,54,392 shares, indicating moderate market participation today.
08What is the P/E ratio of VIMTA LABS and what does it indicate?
VIMTA LABS has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹4.71, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about VIMTA LABS (VIMTALABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.